FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
Ascendiant Capital Markets reiterates a 'Buy' rating, citing significant undervaluation and projecting a potential 1,460% upside for the e-commerce firm.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
The fund, BGTF II, is now the world's largest private fund dedicated to clean energy and decarbonization, signaling strong investor confidence.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.
The China-based education firm's shares plummeted to an all-time low without any immediate news, deepening concerns over its financial stability and exchange listing.
The healthcare data firm will leverage Palantir's AI platform to enhance its real-world clinical data network, fueling investor optimism.
Needham and Cantor Fitzgerald initiate 'Buy' ratings while unconfirmed partnership rumors with Tesla fuel significant buying pressure.